The global cell therapy raw materials market was valued at USD 4.67 billion in 2024 and is projected to reach USD 12.59 billion by 2030, growing at a CAGR of 18.16% from 2025 to 2030. Market growth is driven by continuous innovation in cell culture products—including media, sera, and supplements—as well as the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders.
Increasing investments and funding in cell therapy research further support market expansion. For example, in August 2023, NK:IO Limited raised USD 3.50 million (EUR 3.2 million) to advance cell therapy targeting solid tumors. As more companies pursue R&D efforts in this field, demand for essential raw materials—such as cell culture media, sera, and related supplements—continues to rise. These components are crucial for cultivating, expanding, and preparing therapeutic cells prior to patient administration.
Advancements in biotechnology and cell culture techniques, including three-dimensional cell culture, aseptic processing, and improved cell preservation methods, have also played a significant role in accelerating industry growth. These innovations have enabled more efficient and cost-effective manufacturing workflows, lowering production costs and making cell therapies more accessible to broader patient populations. This, in turn, fuels the need for high-quality raw materials.
Key Market Trends & Insights
- North America dominated the market with a 47.30% share in 2024.
- By product, the cell culture supplements segment accounted for the largest share at 25.27% in 2024.
- By end use, biopharmaceutical & pharmaceutical companies represented the largest segment at 53.54% in 2024.
Download a free sample PDF of the Cell Therapy Raw Materials Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 4.67 Billion
- 2030 Projected Market Size: USD 12.59 Billion
- CAGR (2025–2030): 18.16%
- Largest Market (2024): North America
- Fastest-Growing Region: Asia Pacific
Competitive Landscape
Companies operating in the cell therapy raw materials market are pursuing product approvals to expand their global reach, increase product availability, and support broader production and research activities. Many players are also engaging in strategic acquisitions of smaller companies to strengthen their market presence, enhance technological capabilities, and broaden product portfolios.
Prominent Companies
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher
- Sartorius Stedim Biotech
- Actylis
- ACROBiosystems
- STEMCELL Technologies
- Grifols, S.A.
- Charles River Laboratories
- RoosterBio, Inc.
- PromoCell GmbH
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The cell therapy raw materials market is poised for strong growth, driven by rapid biotechnological advancements, increasing therapeutic demand, rising investments, and expanding research activity. As cell therapies become more widely adopted across clinical applications, the need for high-quality, reliable, and scalable raw materials will continue to surge. Companies that invest in innovation, capacity expansion, and strategic partnerships are well positioned to capitalize on the significant opportunities emerging within this dynamic and rapidly evolving market.
No comments:
Post a Comment